Data as of Aug 29
| +0.17 / +1.08%|
The 8 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 35.50, with a high estimate of 45.00 and a low estimate of 31.00. The median estimate represents a +123.13% increase from the last price of 15.91.
The current consensus among 8 polled investment analysts is to Buy stock in Celldex Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.